Ken Griffin Sana Biotechnology, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Sana Biotechnology, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 45,800 shares of SANA stock, worth $110,836. This represents 0.0% of its overall portfolio holdings.

Number of Shares

45,800

Previous 100,800 54.56%

Holding current value

$110,836

Previous $550,000 65.45%

% of portfolio

0.0%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.76 - $6.86 $450,895 - $822,644	119,919 Added 201.97%	179,294 $745,000
Q2 2024 Aug 14, 2024	SELL	$5.23 - $10.44 $9.56 Million - $19.1 Million	-1,827,781 Reduced 96.85%	59,375 $324,000
Q1 2024 May 15, 2024	BUY	$4.2 - $11.27 $7.76 Million - $20.8 Million	1,847,280 Added 4632.56%	1,887,156 $18.9 Million
Q4 2023 Feb 14, 2024	SELL	$2.8 - $4.55 $687,668 - $1.12 Million	-245,596 Reduced 86.03%	39,876 $162,000
Q3 2023 Nov 14, 2023	BUY	$3.77 - $6.23 $625,970 - $1.03 Million	166,040 Added 139.02%	285,472 $1.1 Million
Q2 2023 Aug 14, 2023	SELL	$3.22 - $7.53 $4.73 Million - $11.1 Million	-1,469,949 Reduced 92.49%	119,432 $711,000
Q1 2023 May 15, 2023	BUY	$3.11 - $4.92 $2.29 Million - $3.63 Million	737,578 Added 86.59%	1,589,381 $5.2 Million
Q4 2022 Feb 14, 2023	SELL	$3.19 - $6.46 $1.07 Million - $2.17 Million	-335,609 Reduced 28.26%	851,803 $3.36 Million
Q3 2022 Nov 14, 2022	BUY	$5.58 - $9.04 $6.25 Million - $10.1 Million	1,119,195 Added 1640.64%	1,187,412 $7.13 Million

Others Institutions Holding SANA

# of Institutions

175

Shares Held

121M

Call Options Held

1.87M

Put Options Held

1.48M

View Full List

About Sana Biotechnology, Inc.

Ticker SANA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 190,232,000
Market Cap $460M
Description
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others...

More about SANA

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account